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https://doi.org/10.1016/j.jtho.2019.07.004Immune checkpoint inhibitors (ICIs) have changed the
treatment paradigm and prognosis in advanced NSCLC.1
However, some subgroups of patients with NSCLC are
usually not enrolled in clinical trials because of their
disease status (i.e., brain metastasis) or underlying
conditions such as a history of autoimmune disease
(AID). The major concerns preventing enrollment of
patients with AID were the risk of unacceptable immune
activation in the form of AID symptom exacerbation
(flares) or the occurrence of new autoimmune manifes-
tations, in particular through inhibition of cytotoxic
T-lymphocyte antigen 4 and programmed death 1/pro-
grammed death ligand 1 axes, which are the main targets
of ICI treatment, with preclinical evidence data
suggesting that these axes may also play a role in AID.2
Immune dysregulation may be associated with height-
ened risk of immune-related adverse events (ir-AEs),
especially among those patients with higher titers of
autoimmunity.3-5 AID cases are relevant in NSCLC
because 14% of patients with NSCLC (especially fe-
males) have a concurrent AID, the most common ones
being rheumatoid arthritis, psoriasis, and polymyalgia.6
A history of AID in patients with NSCLC does not influ-
ence other treatment possibilities and is not associated
with lung cancer–specific and all-cause mortality.7 As
ICIs improve survival in advanced NSCLC, there is an
urge to explore the safety and efficacy of ICIs in this
population.
Real-world data reported that up to 22% of all pa-
tients with advanced NSCLC receiving ICIs have a history
of AID.8,9 Only four retrospective cohorts have assessed
the efficacy and safety of ICIs in NSCLC patients with AID.Two cohorts focused on NSCLC patients, whereas the
other two enrolled patients with different solid tumors
including NSCLC, mainly enrolling patients with non-
symptomatic rheumatologic, dermatologic, and endo-
crine disorders without baseline-specific treatment
(Table 1).8,10-12 Regarding safety, patients with AID had a
higher incidence of ir-AEs, but these were mostly mild
with an incidence of grade greater than or equal to 3 ir-
AEs similar to those reported in the whole population
without AID, and sometimes associated to AID flare.8,10-12
These toxicities rarely required therapy discontinuation
and were manageable with standard treatment
algorithms (Table 1).11,12 More specifically in patientsJournal of Thoracic Oncology Vol. 14 No. 10: 1701-1703
Table 1. Cohorts of Cancer Patients With Autoimmune Disease Treated With Immune Checkpoint Inhibitors
Investigator
Leonardi et al.10 Khozin et al.8 Danlos et al.11 Cortellini et al.12
N/tumor types 56/NSCLC 2402/NSCLC
Real-world data
397/Multiple (NSCLC: 16.3%) 751/Multiple (NSCLC: 66%)
Patients with AID 56 531 (22%) 45 (6 NSCLC, 13%) 85
Active AID 18% NR 56% 17%
Treatment for AID 20% NR 16% 17%
Flare AID 23% NR 24.4% 47.1%
Ir-AEs/grade 3
ir-AEs
38%/11% 27.1% /NR (26.0%/NR
for non-AID)
44% / 11% (29% / NR for
non-AID)
66%/9.4% (40%/9% for non-AID)
Discontinued 14% NR 11.1% 7% (7.2% for non-AID)
RR 22% NR 38% (28% RR for non-AID,
p ¼ 0.098)
38% inactive-AID, 50% active-AID
(35% for non-AID)a
PFS, months NR p ¼ 0.74 NR 6.8 active-AID, 14.4 inactive-AID,
8.0 no-AIDa
OS, months NR 11.5 vs. 12.8,
p ¼ 0.13
p ¼ 0.38 9.8 active-AID, 15.7 inactive-AID,
16.5 no-AIDa
All studies were retrospective.
AID types according to the cohorts were as follows:
Leonardi et al.10: rheumatologic disorder (45%), dermatologic disorder (29%), endocrine disorder (16%), inflammatory bowel disease (11%), neurologic condition
(5%), rheumatic fever (3%), and autoimmune hemolytic anemia (2%). Seven patients had more than one autoimmune disease.
Khozin et al.8: glucocorticoid deficiency (3.9%), rheumatoid arthritis (5.8%), and sacroiliitis (3.9%).
Danlos et al.11: Thirty-six patients had a pre-existing AID other tan vitiligo: cutaneous psoriasis (n ¼ 12, including 1 case with psoriatic arthritis), autoimmune
thyroiditis (Hashimoto disease or Grave’s disease; n ¼ 7), primary Sjögren’s syndrome (n ¼ 4), rheumatoid arthritis (n ¼ 2), immune thrombocytopenic purpura
(n ¼ 1), spondyloarthritis (n ¼ 1), multiple sclerosis (n ¼ 2), hidradenitis suppurativa (n ¼ 1), myasthenia gravis (n ¼ 1), polymyalgia rheumatica (n ¼ 1),
polyarteritis nodosa (n ¼ 1), sarcoidosis (n ¼ 1), chronic cutaneous lupus (n ¼ 1), and type 1 diabetes (n ¼ 1). Two concomitant AID cases were reported in 18%
of cases.
Cortellini et al.12: thyroid disorders (60%), dermatologic (16.4%), rheumatologic (11.8%), gastrointestinal/hepatic (4.7%), neurologic/ nephrologic (w1%), and
multiple sites (4.7%).
aDifferences were not statistically significant (AID vs. non-AID).
AID, autoimmune disease; ir-AEs, immune-related adverse events; NR, not reported; OS, overall survival; PFS, progression-free survival; RR, response rate.
1702 Remon et al Journal of Thoracic Oncology Vol. 14 No. 10with NSCLC, the incidence of grade 3 ir-AEs and discon-
tinuation rate were 11% and 14%, respectively.10 This
was similar to what has been reported in randomized
trials in previously treated NSCLC patients (grade 3 ir-
AEs ranging from 5% to 16%, and up to 8% of treatment
discontinuation).13 An observational study has reported
that pre-existing AID was not associated with time to any
hospitalization after initiating ICI therapy, but it was
associated with a modest increase in hospitalizations with
ir-AE diagnoses and with corticosteroid treatment.14
Furthermore, 25% to 47% of AID patients treated with
ICI may experience an exacerbation of their underlying
AID, being the cause of grade 3 ir-AEs in some cases.10-12
The majority of these flares are detected within the first 3
months of ICI treatment, without late occurrence, with a
trend toward risk of flare among patients with pre-
existing thyroid, dermatologic, or gastrointestinal/hepat-
ic disorders.10,12 However, it remains unknown whether
this hypothetical correlation is truly organ-specific, or
whether it is only related to the fact that these ones are
ones of the most frequent AID cases.
Besides safety, ICI efficacy in this population was
similar to those without AID, with a response rate
ranging from 22% in the NSCLC cohort to up to 39% in
the other two cohorts.10-12 Previous data have reported
contradictory results regarding the role of baselineautoimmunity in NSCLC patients treated with ICI and
outcome, despite the fact that increased risk of ir-AEs
has been correlated with better outcome.4,5 In three of
four current cohorts, outcome was similar for AID and
non-AID patients, but patients with active AID had a
shorter survival.8,10,11 In the reported AID cohorts, be-
tween 20% and 56% of patients were symptomatic at
the time of ICI initiation, and up to 20% were receiving
immunosuppressant or immunomodulatory treatments
for their AID.10-12 It has been previously reported that
concurrent administration of steroids during the first
cycle of ICI as well as within 30 days of the start of ICIs
correlates with decreased outcome.15,16 However, this
correlation seems linked to the dose and duration of
steroids16 and to the use of corticoesteroids for palliative
conditions.17 Use of immunosuppressant drugs in pa-
tients with active AID may potentially explain the
shorter outcome with ICI in this population as compared
with patients with inactive AID and with non-AID pa-
tients (Table 1).12 All these cohorts have the limitations
that they were retrospective and enrolled mild-
symptomatic AID patients without any life-threating
AID. Therefore, we cannot extrapolate the current
evidence to more severe AID patients. Prospective
evaluation of the ICI strategy in patients with AID re-
mains challenging. Two phase I clinical trials with the
October 2019 ICIs in NSCLC With Autoimmune Disease 1703anti–programmed death 1 antibody nivolumab in lung
cancer (NCT03656627) and across tumor types
(NCT03816345) are ongoing in this population.
In conclusion, current data suggests that ICIs are a
reasonable strategy in patients with some quiescent AID
and life-threatening malignancies, without effective
alternative treatments. There is a risk of AID exacerba-
tions in up to half of cases, which usually are manageable
without increased risk of hospitalizations. However, a
discussion about risk-benefit with the patient, as well as
a close monitoring of these patients by a multidisci-
plinary team are necessary to identify AID flares and
implement an early therapeutic intervention. In addition,
before broadly applicability of ICI in all patients with
AID, larger studies are necessary to identify risk of ICI in
case of more severe and symptomatic AID or in patients
with specific AID subtypes, very few represented in the
current retrospective cohorts.
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